{"filings":[{"id":95210,"accession_number":"0001193125-26-137909","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.","$380M PIPE into Korsana led by institutional investors concurrent with merger.","Pre-merger Cyclerion shareholders get CVRs for future proceeds from Akebia license, Tisento stock, and other legacy assets.","Combined co board of 6 all Korsana designees; CEO to be Korsana's president and CEO.","Merger expected to close Q3 2026; subject to Cyclerion shareholder vote, HSR, Nasdaq approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108099,"accession_number":"0001193125-26-053035","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion receives positive FDA feedback for CYC-126 Phase 2 POC study in TRD; remains on track for 2H 2026 initiation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).","Remains on track to initiate Phase 2 POC study in 2H 2026; first patient in Australia, U.S. enrollment in 1H 2027.","Formed Clinical Advisory Board with five key leaders in neuropsychiatry, anesthesiology, and clinical development.","Selected contract research organization to support multinational study execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108098,"accession_number":"0001193125-26-003509","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion Therapeutics enters collaboration with Medsteer for CYC-126 anesthetic delivery system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cyclerion entered a Collaboration and Option Agreement with Medsteer for an anesthetic delivery system for treatment-resistant depression.","Medsteer granted an exclusive option for a worldwide license of its technology, with upfront nominal payment and up to $3.7M in milestones.","Cyclerion plans to initiate Phase 2 proof-of-concept study of CYC-126 in second half of 2026, targeting first patient in Australia.","Medsteer's technology has been used in over 9,000 patients and 25 clinical settings.","Collaboration includes joint development of closed-loop anesthetic delivery platform with real-time EEG monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124518,"accession_number":"0001193125-25-304067","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.","Under license amendment, Cyclerion is owed $1.0M upon first patient dosed in a US Phase 2 trial.","The milestone payment is not yet due as dosing has not begun."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141195,"accession_number":"0001193125-25-213332","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.","Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.","Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.","Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158996,"accession_number":"0001193125-25-142765","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclerion shareholders elect all six director nominees at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with >1.3M votes for each; broker non-votes 743,285.","Ratification of Ernst & Young as auditor approved with 2,072,684 for, 57,547 against.","Advisory say-on-pay passed with 1,312,697 for, 78,221 against, 6,203 abstain.","Shareholders selected one-year frequency for future advisory votes on executive compensation.","Proposal to adjourn meeting if needed also approved with 2,036,703 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158995,"accession_number":"0001193125-25-115089","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cyclerion enters $20M ATM equity distribution agreement with Guggenheim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Guggenheim Securities for at-the-market offering of up to $20M of common stock.","Guggenheim will receive 3% commission on gross proceeds; sales limited by public float under Instruction I.B.6.","Company has not sold any securities under Instruction I.B.6 in prior 12 months; current public float below $75M.","Legal opinion from Ropes & Gray covers sale of up to $2,994,080 of Shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177438,"accession_number":"0001193125-25-062612","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cyclerion raises $1.375M in private placement of 499,998 shares at $2.75/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 499,998 shares at $2.75 each to insiders Peter Hecht and Michael Higgins.","Gross proceeds $1.375M; net for general corporate purposes.","Private placement closed March 25, 2025; shares unregistered under Securities Act.","Registration rights agreement requires filing registration statement by May 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194171,"accession_number":"0001193125-24-280125","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.","Tiered royalties increased to mid-single-digit to 20% on net sales; some development milestones reduced.","Exclusive license option for olinciguat granted to entity controlled by CVCO Therapeutics; grantee pays IP costs.","Proceeds will fund CNS pipeline build; company plans to raise capital as needed to support product plans.","Olinciguat option, if exercised, would complete monetization of Cyclerion's historical sGC stimulator portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210491,"accession_number":"0001193125-24-195410","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion promotes Regina Graul, Ph.D., to CEO and President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Regina Graul, Ph.D., promoted to CEO, President, and Board member effective August 7, 2024.","Graul joined Cyclerion as President in December 2023 and led cost reduction and business development efforts.","Company reducing operating costs while evaluating multiple business development prospects for asset in-licensing.","Errol DeSouza, Ph.D., Board Chair, cites Graul's work in assessing new therapies and enhancing shareholder value.","No financial guidance or financial results provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228825,"accession_number":"0001193125-24-161591","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclerion Therapeutics shareholders re-elect all five directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each of five director nominees (De Souza, Hecht, Hyman, Higgins, Katabi) elected with for votes ranging from 1,670,155 to 1,688,966.","Ernst & Young ratified as independent auditor for FY 2024 with 2,140,990 votes for, 47,974 against, 8,751 abstain.","Proposal to adjourn annual meeting if necessary approved with 2,111,217 for, 86,202 against, 296 abstain.","Broker non-votes on director election were 454,351 for each nominee; no other proposals had broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228824,"accession_number":"0001193125-24-100763","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cyclerion sets 2024 annual meeting for June 14, 2024; record date April 17, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting to be held on June 14, 2024 in virtual format.","Record date for shareholder voting is April 17, 2024.","Definitive proxy statement to be filed with SEC by April 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}